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ABSTRACT
Background: Angiogenesis, the growth of new blood
vessels, is a critical homeostatic mechanism which
regulates vascular populations in response to physiologi-
cal requirements and pathophysiological demand, includ-
ing chronic inflammation and cancer. The importance of
angiogenesis in gastrointestinal chronic inflammation and
cancer has been defined, as antiangiogenic therapy has
demonstrated benefit in models of inflammatory bowel
disease and colon cancer treatment. Curcumin is a natural
product undergoing evaluation for the treatment of
chronic inflammation, including inflammatory bowel
disease (IBD). The effect of curcumin on human intestinal
angiogenesis is not defined.
Methods: The antiangiogenic effect of curcumin on in
vitro angiogenesis was examined using primary cultures
of human intestinal microvascular endothelial cells
(HIMECs), stimulated with vascular endothelial growth
factor (VEGF).
Results: Curcumin inhibited proliferation, cell migration
and tube formation in HIMECs induced by VEGF.
Activation of HIMECs by VEGF resulted in enhanced
expression of cyclo-oxygenase-2 (COX-2) mRNA, protein
and prostaglandin E2 (PGE2) production. Pretreatment of
HIMECs with 10 mM curcumin as well as 1 mM NS398, a
selective inhibitor of COX-2, resulted in inhibition of COX-2
at the mRNA and protein level and PGE2 production.
Similarly COX-2 expression in HIMECs was significantly
inhibited by Jun N-terminal kinase (JNK; SP600125) and
p38 mitogen-activated protein kinase (MAPK; SB203580)
inhibitors and was reduced by p44/42 MAPK inhibitor
(PD098059).
Conclusions: Taken together, these data demonstrate an
important role for COX-2 in the regulation of angiogenesis
in HIMECs via MAPKs. Moreover, curcumin inhibits
microvascular endothelial cell angiogenesis through
inhibition of COX-2 expression and PGE2 production,
suggesting that this natural product possesses anti-
angiogenic properties, which warrants further investiga-
tion as adjuvant treatment of IBD and cancer.
Vascular endothelial growth factor (VEGF) plays
an essential role in endothelial proliferation and
angiogenesis during embryonic development as
well as periods of increased physiological, demand
including the menstrual cycle, pregnancy and
wound healing.
12 Enhanced expression of VEGF
also occurs in disease conditions leading to
pathological angiogenesis including chronic inflam-
mation (ie, rheumatoid arthritis, psoriasis, inflam-
matory bowel disease (IBD)), diabetic retinopathy
and adenocarcinoma.
3 The importance of angio-
genesis in disease processes has been demonstrated
by the success of antiangiogenic therapeutic trials,
which are approved for the treatment of advanced
colorectal adenocarcinoma.
4 VEGF plays a key role
in cancer biology and contributes to tumour
neovascularisation in response to the increased
demand for delivery of nutrients and oxygen.
5–7 In
the setting of chronic inflammation, antiangio-
genic therapy has shown beneficial effects in
animal models of IBD (Crohn’s disease, ulcerative
colitis)
8 as well as open-label trials of the com-
pound thalidomide in refractory Crohn’s disease.
Thecyclo-oxygenase(COX)enzymesareinvolved
in numerous physiological responses including
inflammation, where they catalyse the synthesis of
prostaglandins (PGs) from arachidonic acid. COX-1
is one of the two COX isoforms, and is responsible
for maintaining normal physiological functions; it is
expressed constitutively in most tissues. In contrast,
COX-2 is an early response gene induced by growth
factors, proinflammatory cytokines, tumour promo-
ters and bacterial toxins.
9–11 Inhibition of COX-2 by
non-steroidal anti-inflammatory drugs (NSAIDs)
results in inhibition of angiogenesis and down-
regulation of angiogenic factors such as VEGF and
bFGF-2 (basic fibroblast growth factor).
12–14 In
human colorectal adenocarcinoma and other malig-
nancies such as breast, cervical, prostate and lung
tumours, increased COX-2 expression has been
reported.
15 16 In mice, inhibition of COX-2 has been
shown to protect against intestinal polyposis.
17 The
precise mechanisms whereby COX-2 contributes to
tumourigenesis include effects on the epithelium,
but additional effects on non-epithelial populations
including the microvascular endothelium have also
been suggested.
11
Curcumin, the major yellow colouring pigment
found in the household spice turmeric (Curcuma
longa Linn, Zingiberaceae), has been used for
centuries in food preparation as well as in
Ayurvedic traditional medicine to treat inflamma-
tory disorders.
18 Curcumin has low toxicity and has
been shown to benefit the treatment of chronic gut
inflammation in animal models, as well as showing
benefit in a randomised cross-over trial in the
treatment of ulcerative colitis.
19 Also, curcumin has
been shown to have antineoplastic potential,
inhibiting the development of chemically induced
tumours of the oral cavity, skin, forestomach,
duodenum and colon in rodents.
20–23 The effect of
curcumin on pathological angiogenesis associated
with gastrointestinal disease processes has not
been defined.
Our laboratory has focused investigation on the
microvascular endothelial biology of the human
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intestinal microvascular endothelial cells (HIMECs).
Previously, we have shown that VEGF leads to proliferation of
HIMECs,
24 triggering dephosphorylation, translocation and
activation of NFAT (nuclear factor of activated T cells) in
HIMECs.
25 VEGF activates various signalling pathways such as
phosphatidylinositol 3-kinase (PI3K)/Akt, protein kinase C
(PKC) and mitogen-activated protein kinase (MAPK) cascades.
26
However, the signalling pathways by which VEGF regulates
COX expression in HIMECs are not fully characterised.
In the present study, we examined the effect of curcumin and
MAPK inhibitors on COX-2 gene expression and angiogenesis in
HIMECs following VEGF stimulation. We have shown that
COX-2 plays an important role in VEGF-induced angiogenesis
via MAPKs, and curcumin blocks both COX-2 expression and
angiogenesis induced by VEGF. These results may provide a
mechanistic understanding for the beneficial effects of curcumin
in conditions including chronic inflammation and cancer, where
pathological neovascularisation is associated with an enhanced
expression of VEGF.
MATERIALS AND METHODS
Reagents
Endothelial cell growth supplement (ECGS) was from Upstate
Cell Signaling Solutions (Temecula, California, USA). RPMI
1640 medium, fetal bovine serum (FBS), MCDB-131 medium
and PSF (penicillin/streptomycin/fungizone) were obtained
from Invitrogen (Carlsbad, California, USA). Human plasma
fibronectin was purchased from Chemicon International
(Temecula, California, USA). Porcine heparin was from Sigma
Chemical Co. (St Louis, Missouri, USA). The recombinant
human VEGF, antibodies to intercellular adhesion molecule 1
(ICAM-1), vascular cell adhesion molecule (VCAM) and E-
selectin were purchased from R&D Systems (Minneapolis,
Minnesota, USA). The COX-1/-2 antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, California, USA).
The selective COX-2 inhibitor NS398 and carbacyclin (stable
analogue of PGI2) were obtained from Cayman Chemical (Ann
Arbor, Michigan, USA). Antibodies against phosphorylated and
non-phosphorylated MAPK family members (p44/42 MAPK,
p38 MAPK and JNK (Jun N-terminal kinase)) were from Cell
Signaling Technology (Danvers, Massachusetts, USA). The
MAPK inhibitors (PD098059, SB203580 and SP600125) were
obtained from Calbiochem (La Jolla, California, USA). Immun-
Star and all other electrophoresis reagents were from Bio-Rad
(Hercules, California, USA). Oligonucleotides and primers were
purchased from IDT (Integrated DNA Technologies, Coralville,
Iowa, USA). Fluorescein-conjugated phalloidin was from
Molecular Probes (Eugene, Oregon, USA). Unless otherwise
indicated, all other chemicals used in this study were purchased
from Sigma-Aldrich. All experiments were approved by the
Institutional Review Board of the Medical College of Wisconsin.
HIMEC isolation and culture
HIMECs were isolated and cultured as previously described.
24
Experiments were performed on three independent HIMEC lines
unless otherwise specified. All images displayed were a represen-
tative result of one of the three independent experiments.
Activation and pharmacological modulation of HIMECs
HIMEC activation was achieved following VEGF (50 ng/ml)
stimulation for specified time periods. Curcumin (10 mM),
NS398 (1 mM), SB203580 (5 mM), PD098059 (10 mM) and
SP600125 (10 mM) were used to determine the effect of these
inhibitors on COX-2 expression and angiogenesis.
Cell proliferation assay
A total of 3610
4 HIMECs per well were seeded onto fibronectin-
coated 24-well plates, and proliferation assays were performed
as previously described.
25 After pretreatment with 10 mM
curcumin and 1 mM NS398, 5 mM SB203580, 10 mM
PD098059 and 10 mM SP600125 for 30 min at 37uC, cells were
stimulated with VEGF (50 ng/ml) for 12, 24, 48 and 72 h, or left
untreated. Then, cells were re-suspended and counted in a
Coulter Counter (Coulter, Brea, California, USA). In parallel
experiments, cell viability was assessed by trypan blue exclusion
and was .95%. Each condition was assessed in triplicate.
CellularDNAsynthesiswasassessedby[
3H]thymidineuptake.
25
HIMECs were pulsed with [
3H]thymidine (1 mCi/ml; Amersham,
Arlington Heights, Illinois, USA) and washed with 5% (v/v)
trichloroacetic acid (26) prior to fixation. Using 0.5 N NaOH, the
DNA was precipitated, and supernatants were quantified in a beta
counter. Each condition was assessed in triplicate.
Microscopic wounding assay
To assess the effect of curcumin on HIMEC growth following
angiogenic stimuli, a microscopic wounding assay was per-
formed as described earlier.
25 In brief, a HIMEC confluent
monolayer was scraped along a straight line, and the remaining
monolayer was then incubated with growth medium (without
ECGS), and cells were pretreated for 30 min at 37uC with or
without curcumin (10 mM) or NS398 (1 mM). Then, cells were
stimulated by addition of VEGF (50 ng/ml) or left untreated.
The migration of HIMECs across the demarcation line was
monitored using an inverted microscope. At each time point (0,
24, 48 and 72 h), 10 random fields were counted in a blinded
fashion using an ocular grid. Data were expressed as cells/mm
2,
and each condition was assessed in triplicate.
Endothelial cell chemotaxis assay
HIMECs (3610
4 cells/cm
2) were cultured on fibronectin-coated
polycarbonate filters (8 mm pore size, BD Biosciences, Bedford,
Massachusetts, USA) as previously described.
25 After incubation
in overnight medium containing 2% FBS, HIMECs were
incubated with curcumin (0–20 mM) or NS398 (0–10 mM) for 2
h, and buffers containing VEGF (50 ng/ml) were poured into the
lower compartment of the 12-well plates. When indicated, PGE2
(0.1–1 mM) was added to both upper and lower chambers. After
overnight incubation, cell culture inserts were removed and the
upper surface of the membrane was gently wiped to remove non-
migrated cells. Filters were stained with DiffQuik (Baxter
Scientific, McGraw, Illinois, USA), air-dried, and mounted onto
glass slides. Migrated HIMECs adherent to the lower side of the
membrane were counted (10 random high-power fields (406)p e r
condition in a blinded fashion). Cell viability was .95% as
assessed by trypan blue exclusion. Each condition was assessed in
triplicate, and data were expressed as a mean (SD).
Matrigel in vitro tube formation assay
HIMEC tube formation was assessed using Matrigel, as
described previously.
25 Where indicated, the culture medium
was supplemented with various inhibitors as above, while
control wells contained no inhibitors. Using an inverted phase
contrast microscope, HIMEC tube formation was assessed. Five
high-power fields per condition were examined and experiments
were repeated in three independent HIMEC cultures.
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Confluent HIMEC monolayers were assayed as previously
described.
27 Briefly, HIMECs were pretreated for 2 h with
curcumin (0–20 mM) then stimulated with 50 ng/ml VEGF for 8
h. The concentration of PGE2 and 6-keto PGF1a (the stable
metabolite of PGI2) in the culture supernatant was determined
using a commercial ELISA (Cayman Chemical). To determine
COX isozymes which produce PGE2 and PGI2, HIMECs were
pretreated with NS398 (0–10 mM), the COX-2-specific inhibi-
tor, for 2 h then stimulated with 50 ng/ml VEGF for 8 h. The
concentration of PGE2 and 6-keto PGF1a was determined as
described above. Experiments were carried out in triplicate, and
results are shown as mean pg/ml (SD).
RNA preparation and semi-quantitative reverse transcription–
PCR (RT–PCR)
COX-1 and COX-2 mRNA expression were determined as
described previously.
25 PCR amplifications were performed as
follows: 30 cycles for COX-1 (94uC for 1 min, 56uC for 1 min,
72uC for 1 min), 35 cycles for COX-2 (94uC for 1 min, 54uC for
1 min, 72uC for 1 min) and 25 cycles for b-actin (94uC for
1 min, 60uC for 1 min, 72uC for 1 min), using COX-1 forward
(59-TGC CCA GCT CCT GGC CCG CCG CT-39) and reverse
(59-TTC AAA TGA GAT TGT GGG AAA ATT GTC-39); COX-
2 forward (59- TCA AAT GAG ATT GTG GGA AAA TTG-39)
and reverse (59-TCT AGT AGA GAC GGA CTC ATA GAA-39);
and b-actin forward (59-CCA GAG CAA GAG AGG CAT CC-39)
and reverse (59-CTG TGG TGG TGA AGC TGT AG-39)s p e c i f i c
primers, followed by final extension for 7 min at 72uC. The PCR
products were visualised on 1.2% agarose gels stained with
ethidium bromide. RNA solution without reverse transcription
was used as negative control (no RT), and b-actin served as an
internal control.
Western blot analysis
Confluent HIMEC monolayers in 35 mm culture dishes (one dish
per condition) were pretreated with various inhibitors for 30 min
or left untreated before VEGF activation (50 ng/ml) for different
time periods. Sodium dodecylsulfate–polyacrylamide gel electro-
phoresis (SDS–PAGE) and western blot analysis were performed
using antibodies to COX-1, COX-2 and MAPKs as described
previously.
25 Detection was by secondary antibody coupled to
horseradish peroxidase (HRP) and Immun-Star (Bio-Rad).
Immunofluorescence staining
HIMEC monolayers were grown on coverslips to 80% confluence.
Following curcumin or NS398 treatment and VEGF activation,
monolayers were rinsed once in phosphate-buffered saline (PBS),
fixed with cold methanol for 30 min and blocked with 5% bovine
serum albumin in PBS with Ca
2+ and Mg
2+ for 60 min. Using
COX-2 antibody, followed by a fluorescein isothiocyanate
(FITC)-conjugated secondary antibody (Santa Cruz
Biotechnology), the effect of curcumin on COX-2 expression
was visualised. Coverslips were mounted on Superfrost slides
(Fisher Scientfic) with Prolong Antifade mounting medium
(Invitrogen) and visualised using a fluorescence microscope
(Olympus BX-40) and a Leica DFC 300FX camera.
Assessment of cell adhesion molecule (CAM) surface expression
by tumour necrosis factor a (TNFa)/lipopolysaccharide (LPS) in
HIMECs
CAM surface expression in HIMECs was assessed following
TNFa/LPS (100 U/ml TNFa,1mg/ml LPS) activation with or
without 10 mM curcumin pretreatment using radioactive
immunoassay (RIA) and flow cytometry (fluorescence activated
cell sorting (FACS)) as described previously.
28 29
Leucocyte adhesion assay on HIMECs
Leucocyte–HIMEC interaction with or without 10 mM curcu-
min pretreatment was assessed using a low shear stress flow
adhesion assay and U-937 cells as described previously.
28 29
RESULTS
VEGF induced increased COX-2 expression in HIMECs
Activation of HIMECs with 50 ng/ml VEGF resulted in
enhanced COX-2 expression at the mRNA level as detected by
RT–PCR using COX-2 primers. Enhanced COX-2 mRNA
expression was time dependent, increasing by 3 h, and declining
by 18 h (fig 1A). b-Actin gene expression was used as an internal
control in these experiments. In marked contrast, levels of
COX-1 mRNA expression remained unchanged following VEGF
stimulation of HIMECs (Fig. 1A).
Next we determined the effect of VEGF on COX-2 protein
expression by western blotting using a specific COX-2 antibody.
VEGF strongly and time dependently (6–24 h) enhanced the
expression of COX-2 protein in HIMECs (fig 1B). There was no
detectable change in the level of COX-1 protein after VEGF
stimulation (fig 1B).
Corresponding to the effect of VEGF on COX-2 mRNA and
protein expression, the ELISA results from the HIMEC culture
supernatant demonstrated that VEGF (50 ng/ml) stimulation
for 12 h significantly increased PGE2 and 6-keto PGF1a produc-
tion (fig 1C).
Curcumin inhibits COX-2 expression and PGE2 production in
HIMECs
Next we examined the effect of curcumin on COX-2 gene and
protein expression. Pretreatment of HIMECs with curcumin
abolished VEGF induction of COX-2 mRNA expression in a
dose-dependent fashion (fig 2A). Consistent with the gene
expression data, curcumin pretreatment of HIMECs inhibited
COX-2 protein expression at 1 mM, with increasing effect at
10 mM curcumin, while 20 mM curcumin completely abolished
COX-2 expression following VEGF activation (fig 2B). The
selective inhibitor of COX-2, NS398 (1 mM), abolished COX-2
mRNA and protein expression in HIMECs following VEGF
activation (not shown). In addition, immunofluorescence
staining of HIMECs pretreated with either 10 mM curcumin
or 1 mM NS398 demonstrated inhibition of COX-2 expression
following VEGF activation (fig 2C).
Corresponding with the effect on COX-2 expression, curcu-
min inhibited both PGE2 and 6-keto PGF1a production in a dose-
dependent fashion as determined by ELISA measurement of
HIMEC culture media (fig 2D). PGE2 and 6-keto PGF1a
production were completely inhibited by 1 mM NS398 (pre-
treatment), indicating that production of this prostanoid is
dependent on COX-2 activity in HIMECs (fig 2E).
Curcumin inhibits HIMEC growth, proliferation, migration and
tube formation
Angiogenesis involves multiple events in endothelial cells,
including cell migration, proliferation and tube formation.
Previously, we have demonstrated that VEGF activation of
HIMECs resulted in cell migration, proliferation, tube and stress
fibre formation.
25 To determine the antiangiogenic potential of
curcumin and its potential mechanism of action through
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following VEGF stimulation measuring growth, proliferation,
transmigration and tube formation were performed in HIMECs,
using NS398 as a specific COX-2 inhibitor.
Initial experiments were performed evaluating endothelial
growth in a wounded monolayer, with cell expansion across a
leading edge.
30 Figure 3A demonstrates a potent angiogenic
effect of VEGF compared with control cells. Curcumin-
pretreated HIMEC monolayers were unresponsive to VEGF,
and grew at rates almost similar to those of untreated cells.
Curcumin demonstrated no toxicity at the dosages used in this
study. The COX-2 inhibitor NS398 was a potent inhibitor of
endothelial cell growth.
We next performed in vitro growth studies to assess the effect
of curcumin on HIMEC growth. Cell cycle re-entry and DNA
replication in endothelial cells is a requisite step in angiogenesis.
Proliferation was determined by measuring both [
3H]thymidine
uptake and cell enumeration using a Coulter counter.
[
3H]Thymidine uptake was significantly increased after VEGF
treatment, and VEGF stimulation for 18 h also significantly
increased cell number. Curcumin pretreatment of HIMECs
following VEGF activation resulted in inhibition of
[
3H]thymidine uptake and reduced cell number significantly
(fig 3B). The cellular viability remained .98% in all groups (data
not shown). The inhibitory effect of curcumin on HIMEC
[
3H]thymidine uptake was reversed by addition of the PGI2
analogue carbacyclin (fig 3C). Proliferation of HIMECs in
response to VEGF was completely inhibited by both curcumin
and the COX-2 inhibitor NS398.
Pretreatment of HIMECs with either curcumin or the COX-2-
specific inhibitor NS398 resulted in inhibition of endothelial
transmigration and tube formation. Curcumin pretreatment of
HIMECs inhibited VEGF-induced transmigration, which was
similar to the effect of the COX-2-specific inhibitor NS398
(fig 3D). The endothelial in vitro tube formation assay using
Matrigel was performed in the absence and presence of
curcumin or NS398 following VEGF activation. The number
of endothelial tubes formed in Matrigel was significantly
inhibited by both curcumin and NS398 (fig. 3E). The inhibitory
effect of curcumin on endothelial tube formation was reversed
by carbacyclin (not shown). These results indicate that
inhibition of COX-2 activity is linked to impaired HIMEC
angiogenesis in vitro. Finally, curcumin and NS398 both exerted
a potent inhibitory effect on HIMECs, decreasing prostanoid
production as demonstrated above (fig 2E, F).
Pharmacological modulation of HIMECs
Previously we have shown that VEGF stimulation of HIMECs
leads to a marked phosphorylation and activation of all three
MAPK family members (p44/42 MAPK, stress-activated protein
kinase (SAPK)/JNK and p38 MAPK).
25 To investigate whether
MAPK pathways play a role in VEGF induction of COX-2,
HIMECs were pretreated with specific MAPK inhibitors then
activated with VEGF. Our findings show that inhibition of the
MAPK pathways resulted in downregulation and suppression of
COX-2 expression at both the mRNA and protein levels.
Inhibition of p44/42 MAPK by PD098059 (10 mM) inhibited
COX-2 expression. Similarly, pretreatment of HIMECs with
either SB203580 (5 mM) or SP600125 (10 mM), selective inhibi-
tors of p38 MAPK and JNK, respectively, also significantly
inhibited VEGF-induced COX-2 expression at both the mRNA
and protein levels (fig 4A, B). Corresponding to the effect on
COX-2 expression, all three MAPK inhibitors exerted an
inhibitory effect on PGE2 production as determined by ELISA
in HIMEC culture media (fig. 4C). These data suggest that all
MAPK members are involved in upregulation of COX-2
expression by VEGF in HIMECs. In marked contrast, MAPK
inhibitors did not affect COX-1 expression.
Effect of curcumin on MAPK activation in HIMECs
Upregulation of COX-2 expression by VEGF via MAPK-
dependent pathways has been shown in human umbilical vein
endothelial cells.
13 However, it is not known whether curcumin
modulates the expression of COX-2 by inhibition of these
Figure 1 Effect of vascular cell
adhesion factor (VEGF) on cyclo-
oxygenase-1 (COX-1) and COX-2 mRNA
and protein expression in human
intestinal microvascular endothelial cells
(HIMECs). (A) Semi-quantitative reverse
transcription–PCR of COX mRNA in
HIMECs demonstrates that COX-1 mRNA,
but not COX-2, was constitutively
expressed in HIMECs. VEGF (50 ng/ml)
stimulation of HIMECs resulted in marked
upregulation of COX-2 gene expression by
3 h, whereas COX-1 was unaffected. b-
Actin was used as an internal loading
control. (B) Western blot analysis
demonstrates that VEGF enhanced COX-2
protein expression in HIMECs by 6 h,
which persisted until 24 h, declining by
36 h. COX-1 protein expression was not
affected by VEGF. (C) The results of ELISA
for prostaglandin E2 (PGE2) and 6-keto
PGF1a in HIMEC culture supernatants
demonstrate that VEGF stimulation
significantly increased both PGE2 and 6-
keto PGF1a production in HIMECs. Data
are expressed as pg/ml PG production
(SD). *p,0.05 compared with control.
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cells, specifically HIMECs. Thus, we examined the effect of
curcumin on VEGF-induced activation of p44/42 MAPK, p38
MAPK and JNK in HIMECs. Previously we have shown that
VEGF activation of HIMECs would lead to phosphorylation and
activation of all three kinases.
25 To confirm whether curcumin
inhibits the activation of MAPKs in VEGF-activated HIMECs,
these cells were pretreated with curcumin (10 mM) and were
then stimulated by VEGF. As shown in fig 5, phosphorylation of
p44/42 MAPK, p38 MAPK and JNK by VEGF was significantly
decreased by curcumin pretreatment of HIMECs. These results
indicate that curcumin attenuates VEGF-induced COX-2
expression through inhibition of MAPK pathways.
Effect of curcumin on CAM expression in HIMECs following
TNFa/LPS activation
CAM surface expression by endothelial cells is regulated by
cytokines and inflammatory activators.
31 32 Previously, we have
shown that the CAM expression in HIMECs was enhanced in
response to dual inflammatory stimulation with TNFa/LPS.
28 29
Here, we examined the effect of curcumin pretreatment on
CAM expression and leucocyte binding in HIMECs following
TNFa/LPS activation. Figure 6A, using cell surface RIA,
demonstrates that curcumin effectively inhibited the ICAM-1
and VCAM surface expression in response to TNFa/LPS
activation and partially reduced E-selectin expression. Similar
results were obtained from FACS analysis (fig 6B).
Next we performed a low-shear stress flow adhesion assay. As
shown in fig 6C, curcumin (10 mM) pretreatment of HIMECs
inhibited the adhesion of U-937 cells to TNFa/LPS-activated
HIMECs.
DISCUSSION
In this study, we demonstrate that curcumin exerts potent
effects on the angiogenic properties of microvascular endothelial
cells isolated from the human intestine, inhibiting multiple
stages in the angiogenic process. We have demonstrated that
(1) COX-2 induction as well as prostanoid production induced
by VEGF were blocked by curcumin; (2) VEGF-induced growth,
proliferation, transmigration and tube formation in HIMECs,
an in vitro strategy for modelling angiogenesis, were also
inhibited by curcumin; (3) the COX-2-specific inhibitor NS398,
inhibited HIMEC growth, proliferation, transmigration and
tube formation induced by VEGF; and (4) MAPK family
members are involved in VEGF-induced upregulation of COX-
2 and PGE2 production in HIMECs.
The cyclo-oxygenase enzymes COX-1 and COX-2 have been
shown to play an important role in the regulation of
angiogenesis.
33 These enzymes catalyse the conversion of
arachidonic acid to PGH2, the first step in the biosynthesis of
the PGs thromboxane and prostacyclin.
34 In endothelial cells,
COX-1 is constitutively expressed, whereas COX-2 is inducible
in response to various activators such as mitogens, hormones
and inflammatory cytokines.
35
Figure 2 Curcumin inhibits cyclo-
oxygenase-2 (COX-2) expression in
human intestinal microvascular
endothelial cells (HIMECs).
(A) Pretreatment of HIMECs with
curcumin abolished vascular endothelial
growth factor (VEGF) induction of COX-2
mRNA expression in a dose-dependent
fashion. (B) Consistent with the gene
expression data, curcumin pretreatment
of HIMECs inhibited COX-2 protein
expression at 1 mM, increasing at
10 mM, while 20 mM curcumin
completely abolished COX-2 expression
following VEGF activation.
(C) Immunofluorescence staining of
HIMECs pretreated with either 10 mM
curcumin or 1 mM NS398 demonstrated
inhibition of COX-2 expression following
VEGF activation. (D) Curcumin inhibited
both prostaglandin E2 (PGE2) and 6-keto
PGF1a production in HIMECs in a dose-
dependent manner. Prostanoid species
were assessed from HIMEC culture media
u s i n gE L I S A .D a t aw e r ee x p r e s s e da sp g / m l
PG production (SD). *p,0.05 compared
with no stimulation; **p,0.05 compared
with VEGF stimulation. (E) PGE2 and 6-keto
PGF1a production were also completely
inhibited by pre-treatment with 1 mM
NS398. Data were expressed as pg/ml PG
production (SD). *p,0.05 compared with
no stimulation; **p,0.05 compared with
VEGF stimulation.
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on microvascular endothelial growth, proliferation, migration
and tube formation, and suppresses angiogenesis by inhibiting
COX-2 expression and PG production. These data suggest that
the inhibition of in vitro angiogenesis or reduced PG production
will result from the inhibitory effect of curcumin on VEGF-
induced HIMEC activation. Previously we have demonstrated
that VEGF induced COX-2 expression, and COX-derived
Figure 3 Curcumin inhibits growth,
proliferation, migration and tube formation
in human intestinal microvascular
endothelial cells (HIMECs). (A) Potent
angiogenic effect of vascular endothelial
growth factor (VEGF) compared with no
stimulation in HIMECs. Curcumin inhibited
HIMEC growth at rates almost similar to
those of control cells. The cyclo-
oxygenase-2 (COX-2) inhibitor, NS398
was a potent inhibitor of cell growth.
(B) Cellular DNA synthesis was assessed
by measuring [
3H]thymidine uptake.
[
3H]Thymidine uptake was significantly
increased after VEGF stimulation for 15 h
and was inhibited by curcumin
pretreatment for 30 min in a dose-
dependent manner. Assays were done in
triplicate and the data are shown as mean
cpm (SD). *p,0.05 compared with
VEGF-stimulated HIMEC cultures. (C) The
inhibitory effect of curcumin on
[
3H]thymidine uptake was reversed by
addition of carbacyclin (a prostaglandin I2
(PGI2) analogue). *p,0.05 compared
with curcumin-treated HIMECs with no
exogenous PG. (D) The number of
HIMECs transmigrated through the filter
was increased by VEGF stimulation;
curcumin pretreatment of HIMECs
significantly inhibited HIMEC
transmigration, which was reversed by
1 mM carbacyclin. At least 15 random
high-power fields (6200) per condition
were counted and data were expressed
as mean (SD). *p,0.05 compared with
curcumin pretreatment. (E) Phase-
contrast photomicrograph demonstrates
the endothelial in vitro tube formation on
Matrigel; the formation of capillary-like
structures was inhibited by curcumin
pretreatment (640).
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angiogenesis.
27 In the present study, we demonstrate that
curcumin inhibits the angiogenic effect of VEGF-induced COX-
2 mRNA and protein expression as well as PGE2 production in
HIMECs. The inhibitory effect of curcumin on TNFa/LPS-
induced COX-2 expression in HIMECs (data not shown)
indicates that regardless of the type of induction, curcumin is
a potent inhibitor of COX-2 expression and prostanoid
production in endothelial cells. COX-2 expression and prosta-
noid production have been implicated as important mechanisms
in angiogenesis during tumour growth, as COX-2 is upregulated
in the microvasculature surrounding tumours,
36 and inhibition
of COX activity by NSAIDs has been shown to reduce
angiogenesis and tumour growth both in vivo and in vitro.
37 38
The predominant role of endothelial COX-2 versus COX-1 in
angiogenesis remains controversial.
33 In the present study, we
demonstrate that the COX-2 inhibitor NS398 impaired in vitro
angiogenesis in HIMECs, supporting the idea that COX-2-
derived prostanoids play a central role in angiogenesis. The fact
that carbacyclin reversed the inhibition of [
3H]thymidine
uptake, cell migration and tube formation by curcumin also
implicates the central role of COX-2 in HIMEC angiogenesis.
Therefore, the inhibitory effect of curcumin could in part be the
result of suppression of PGI2 formation through inhibition of
COX-2 expression. In addition to the effect of curcumin on
COX-2 expression, curcumin also affects expression of several
genes associated with cell growth and/or apoptosis (eg, Bcl2,
Bax, caspase and PI3K/Akt). Curcumin inhibition of endothelial
nitric oxide synthase (eNOS) expression in endothelial cells has
been shown to contribute to impaired endothelial tube
formation.
39 Taken together, our results suggest that the
antiangiogenic activity of curcumin involves modulation of
multiple pathways in endothelial cells.
The importance of antiangiogenic agents in the treatment of
cancer is well established, and their role in the treatment of
chronic inflammatory disorders is gaining momentum. Work in
rheumatoid arthritis as well as human IBD has demonstrated a
central role for angiogenesis in the pathophysiology of these
chronic inflammatory diseases. Use of novel antiangiogenic
agents in the treatment of animal models of IBD has also shown
benefit. In experiments by Danese et al
8 using ATN-161, a
peptide inhibitor of the proangiogenic avb3/a5b1 integrins, a
significant therapeutic effect was shown in interleukin 10 (IL10)
knockout mice. The IL10 knockout mouse is felt to be an
established model of chronic inflammatory injury and remodel-
ling in the gastrointestinal tract, and animals treated with this
antiangiogenic compound showed improvement in their disease
activity index, an improved histological colitis score with a
parallel decrease in intestinal microvessel density.
Figure 4 Modulation of cyclo-oxygenase-2 (COX-2) expression in
human intestinal microvascular endothelial cells (HIMECs) by mitogen-
activated protein kinase (MAPK) inhibitors. (A and B) Inhibition of the
MAPK pathways resulted in downregulation and suppression of COX-2
mRNA and protein. Pretreatment of HIMECs with either 10 mM
PD098059 (p44/42 MAPK), 5 mM SB203580 (p38 MAPK) or 10 mM
SP600125 (Jun N-terminal kinase) significantly inhibited vascular
endothelial growth factor (VEGF)-induced COX-2 mRNA and protein
expression. (C) All three MAPK inhibitors inhibited prostaglandin E2
(PGE2) production as determined by ELISA in HIMEC culture media.
*p ,0.05 for inhibitors vs VEGF.
Figure 5 Curcumin inhibits the activation of mitogen-activated protein
kinases (MAPKs) in vascular endothelial growth factor (VEGF)-activated
human intestinal microvascular endothelial cells (HIMECs). Pretreatment
of HIMECs with 10 mM curcumin following VEGF activation resulted in
inhibition of p44/42 MAPK, p38 MAPK and Jun N-terminal kinase (JNK)
phosphorylation.
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human IBD has undergone limited exploration. The proto-
typical antiangiogenic agent thalidomide has been shown to
benefit patients with refractory Crohn’s disease, but is fraught
with problems, including its terrible legacy of causing severe
birth defects during its early clinical use as well as unacceptable
rates of neuropathy as an adverse reaction when employed on a
long-term basis.
40 41 Two open-label pilot studies of low-dose
thalidomide in chronically active, steroid-dependent Crohn’s
disease showed benefit, but did not demonstrate whether an
antiangiogenic effect was present in the responding patients.
42
The potential for selective and non-selective COX antagonists
as antiangiogenic agents for the treatment of IBD is also
problematic, as these agents will typically worsen bowel injury
in animal models of the disease and have also been linked to
clinical deterioration in IBD patients.
43–46 Therefore, the addition
of curcumin, as an antiangiogenic agent which does not have
the potential for clinical adverse side effects, may prove to be of
significant benefit. At present, the majority of agents used for
the treatment of IBD are felt to function through the inhibition
of inflammatory mechanisms, or specifically blocking inflam-
matory cytokines, and the addition of an antiangiogenic
compound may exert unique therapeutic benefit.
The use of antiangiogenic agents in the treatment of
gastrointestinal malignancies has emerged as the standard of
care for metastatic lesions.
47 The anti-VEGF antibodies bevaci-
zumab and cetuximab have proved successful in clinical trials,
and optimal regimens for the use of these agents in patients
with metastatic colorectal adenocarcinoma are being defined.
48
The potential for ‘‘cocktails’’ of antiangiogenic agents which
may target multiple mechanisms in the angiogenic process has
also been shown. In the case of mesenteric desmoids, a benign
tumour with no standard treatment regimen, our group has
shown that combination antiangiogenic therapy with toremi-
fene and interferon a2b was effective in causing regression of
these lesions.
49 Therefore, the potential for the addition of
curcumin in combination with other antiangiogenic strategies
warrants evaluation.
In summary, our present study indicates that curcumin is a
potent inhibitor of angiogenesis in HIMECs in vitro. Curcumin
appears to exert its antiangiogenic effect through inhibition of
COX-2 expression and prostanoid production. Given the
importance of angiogenesis and tumour neovascularisation in
cancer progression, our data also suggest that the anticancer
effects of curcumin may also involve direct effects on local
microvascular populations. Future clinical studies evaluating the
long-term benefit of curcumin as an antiangiogenic agent in the
treatment of chronic gut inflammation and bowel cancers are
warranted.
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